BioSpace News Archive

LAIX Inc. announced that it will report its fourth quarter and full year 2018 unaudited financial results on Wednesday, February 27, 2019, before the open of the U.S. markets.

Fire & Flower Holdings Corp. is pleased to announce that its subsidiary, Fire & Flower Inc., has entered into agreements with two of the initial 25 applicants that have been selected by the Alcohol and Gaming Commission of Ontario to apply for cannabis Retail Operator Licences in the East Region of Ontario.

The disease systemic lupus erythematosus — marked by the attack on joints, skin, and kidneys by the body’s immune system — is linked to an abnormal mix of bacteria in the gut.

Axonics Modulation Technologies, Inc. disclosed positive top-line results from the ARTISAN-SNM pivotal study, designed to gain marketing approval from the U.S. Food & Drug Administration for the Axonics r-SNM® System1.

Pfizer Inc. and Eli Lilly and Company announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain.

AGC Biologics and Calypso Biotech B.V. announced that they have entered into an agreement for the process development and cGMP manufacture of CALY-002, a humanized monoclonal antibody inhibiting Interleukin-15.

AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance

TriNetX announced the release of its Treatment Pathways analytic, the latest self-service capability enhancing and simplifying the analysis of real-world data.

New endeavor will advance blood-based biopsies and other technologies to speed cancer diagnosis and track patients’ response to therapies

Inhibrx, Inc., a clinical-stage biotechnology company developing a broad pipeline of novel biologic therapeutic candidates, announced that dosing has begun in a Phase 1 dose-escalation clinical trial of INBRX-105.